Biotechnology News and Research

RSS

Microfluidics reports $143,000 net income for second-quarter 2010 vs. $177,000 loss in second-quarter 2009

Microfluidics International Corporation, today reported unaudited financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Elan to offer $200 million in aggregate principal amount of 8.75% senior notes due 2016

Elan Corporation, plc today announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., intend to offer, subject to market conditions, US$200 million in aggregate principal amount of 8.75% senior notes due 2016.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

Advanced Cell Diagnostics, Inc., announces the launch and immediate availability of RNAscope™ FFPE Assay Kit, a line of RUO products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded tissue specimens with single molecule sensitivity.

From Advanced Cell Diagnostics 11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Teva completes ratiopharm acquisition

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of ratiopharm, Germany's second largest generics producer. Following the acquisition, Teva will be the number one generic company in Europe, holding the leading market position in ten countries, as well as ranking in the top three in seven additional countries. In addition, the transaction will significantly increase Teva's sales in Canada.

10 Aug 2010

PAREXEL International fourth-quarter consolidated service revenue increases 19.4% to $295.3 million

PAREXEL International Corporation today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

From Parexel 10 Aug 2010

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.

10 Aug 2010

Oil rig workers access healthcare via telemedicine

Without hands-on access to doctors and hospitals, oil rig workers who become sick or injured increasingly rely on telemedicine "visits" with physicians and specialists on land, a trend explored in detail in an article published in Telemedicine and e-Health, a peer-reviewed journal published by Mary Ann Liebert, Inc.

10 Aug 2010

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.

10 Aug 2010

Cegedim Dendrite, TAKE Solutions form strategic partnership

As part of the Cegedim Dendrite Alliance Program, created to expand its open business model through alliances with leading technology, software and consulting companies, Cegedim Dendrite today announced its partnership in India with TAKE Solutions Ltd.

10 Aug 2010

New microchip technology to detect oral cancer

A new test for oral cancer, which a dentist could perform by simply using a brush to collect cells from a patient's mouth, is set to be developed by researchers at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.

10 Aug 2010

Talecris and Grifols receive 'Second Request' from FTC regarding proposed merger

Talecris Biotherapeutics Holdings Corp. today announced that Talecris and Grifols S.A. have each received a request for additional information and documentary material, often referred to as a "Second Request," from the U.S. Federal Trade Commission (FTC) in connection with their proposed merger.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Athersys second-quarter revenues increase to $1.9 million

Athersys, Inc. today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

Biotechnology News and Research

Microfluidics reports $143,000 net income for second-quarter 2010 vs. $177,000 loss in second-quarter 2009

Elan to offer $200 million in aggregate principal amount of 8.75% senior notes due 2016

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

China Pharma second-quarter revenue increases 22% to $16.6 million

Teva completes ratiopharm acquisition

PAREXEL International fourth-quarter consolidated service revenue increases 19.4% to $295.3 million

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Oil rig workers access healthcare via telemedicine

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Cegedim Dendrite, TAKE Solutions form strategic partnership

New microchip technology to detect oral cancer

Talecris and Grifols receive 'Second Request' from FTC regarding proposed merger

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Athersys second-quarter revenues increase to $1.9 million

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News